Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Picrotoxin is a naturally occurring plant-derived toxin, primarily obtained from the seeds of *Anamirta cocculus*. It is a mixture of two compounds, picrotoxinin and picrotin. Picrotoxin acts as a noncompetitive antagonist at GABA A receptors (gamma aminobutyric acid type A), blocking the GABA-gated chloride ion channel. This action inhibits the main inhibitory neurotransmitter in the central nervous system, resulting in CNS stimulation and convulsant effects. Historically, it has been used as a central nervous system stimulant and as an antidote for poisoning by CNS depressants such as barbiturates. Due to its high toxicity and risk of inducing seizures or respiratory paralysis at higher doses, its clinical use is now rare; it is mainly used in research settings to study inhibitory neurotransmission[1][2][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on picrotoxin.